In DLBCL, combining ibrutinib and lenalidomide increases activity, especially in non-GCB and ABC-DLBCL, which depend on BCR and MYD88 signaling pathways, NF-κB activation, and upregulation of interferon regulatory factor 4 expression for survival. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.